ArticleFrontiers in aging neuroscience2026
Neuroprotective effects of isoflavone-enriched soybean leaves (
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to investigate the neuroprotective and memory-enhancing effects of isoflavone-enriched soybean leaves (IESLs) against scopolamine-induced cognitive impairment. While soybean leaves (SLs) are naturally rich in kaempferol glycosides and soyasaponins, IESLs are characterized by significantly elevated isoflavone levels through metabolite farming. Methods: To assess the efficacy of IESLs, C57BL/6 mice were orally administered IESLs (6.25 and 18.8 mg isoflavones/kg/day) for 5 weeks, with scopolamine (1 mg/kg, i.p.) administered to induce memory impairment. Spatial learning and memory functions were evaluated using the Morris water maze and passive avoidance tests. Results: Scopolamine-induced behavioral deficits were significantly restored by IESLs administration in a dose-dependent manner. Mechanistically, IESLs treatment reduced the intracellular accumulation of reactive oxygen species and enhanced the antioxidant defense system. Furthermore, IESLs significantly upregulated the expression of brain-derived neurotrophic factor (BDNF) and activated the cAMP response element-binding protein (CREB) via phosphorylation. Histological analysis also revealed that IESLs suppressed the activation of astrocytes and microglia, thereby attenuating neuroinflammation. Discussion: These findings suggest that IESLs effectively alleviate cognitive impairment by strengthening antioxidant defenses and activating the CREB-BDNF signaling pathway. Consequently, IESLs may serve as a promising therapeutic or preventive candidate for amnesia and neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.